GGrantIndex
Sort

48,018 grants matching immunotherapy

Immunoengineering Durable Control of HIV Replication

$1,362,935
Hans-Peter Kiem · University Of Southern California · P01 · FY2025 · HL

Malaria Parasite Genomics, Development, Drug Resistance, Pathogenesis, and host-parasite interaction

$1,362,488
Xinzhuan Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI

BIOLOGY AND TRANSPLANTATION OF THE HUMAN STEM CELL

$1,362,444
University Of Minnesota Twin Cities · P01 · FY2001 · CA

T cell recognition of the MR1 presented microbial metabolome

$1,362,106
Erin June Adams · University Of Chicago · R01 · FY2020 · AI

Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP

$1,358,469
Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

$1,357,000
Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2022 · AI

SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

$1,357,000
Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2023 · AI

SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

$1,357,000
Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2025 · AI

SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

$1,357,000
Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2024 · AI

Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERS

$1,356,966
Reed Johnson · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Acquired Resistance to Therapy and Iron (ARTI) Center

$1,356,931
Boyi Gan · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA

Acquired Resistance to Therapy and Iron (ARTI) Center

$1,356,911
Boyi Gan · University Of Tx Md Anderson Can Ctr · U54 · FY2025 · CA

Acquired Resistance to Therapy and Iron (ARTI) Center

$1,356,890
Boyi Gan · University Of Tx Md Anderson Can Ctr · U54 · FY2022 · CA

Preclinical drug development in pancreatic cancer

$1,356,844
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

SBIR Phase II: Anti-Tumor Immune Redirectors (AIRs) for cancer treatment

$1,355,844
Joshua Wang · Verimmune Inc. · · FY2020 · TIP

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT

$1,355,530
Vanderbilt University · U01 · FY2003 · AI

TGIB Surgical Oncology Fellowship Program

$1,353,932
David Schrump · Division Of Basic Sciences - Nci · ZIE · FY2015 · CA

Immunobiology and immunotherapy of leukemia

$1,353,837
Austin J Barrett · National Heart, Lung, And Blood Institute · ZIA · FY2014 · HL

TGIB Surgical Oncology Fellowship Program

$1,353,606
David Schrump · Division Of Basic Sciences - Nci · ZIE · FY2017 · CA

Mechanisms of Effective Humoral Immune Responses to HIV-1

$1,353,371
Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Trial/ efficacy of immunotherapies to control plasma HIV RNA interrup HAART

$1,352,541
Weill Medical College Of Cornell Univ · M01 · FY2004 · RR

Protein Expression Facility

$1,352,350
Robert Petrovich · National Institute Of Environmental Health Sciences · ZIC · FY2022 · ES

Center for Multiparametric Imaging of Tumor Immune Microenvironments

$1,349,822
Paolo Provenzano · University Of Minnesota · U54 · FY2025 · CA

Novel Strategies for Brain Tumor Therapy

$1,349,527
University Of Pittsburgh At Pittsburgh · P01 · FY2003 · NS

Heat Shock Protein and Thermal Therapy of Cancer

$1,349,240
Roswell Park Cancer Institute Corp · P01 · FY2004 · CA